The Effects of Care Management on Depression Treatment in a Psychiatric Clinic: A Randomized Controlled Trial.

The effects of care management on depression treatment in a psychiatric clinic: a randomized controlled trial.

Filed under: Depression Treatment

Int J Geriatr Psychiatry. 2012 Dec 17;
Jeong H, Yim HW, Jo SJ, Nam B, Kwon SM, Choi JY, Yang SK

OBJECTIVE: This study aims to examine whether care management has an effect on adherence to depression treatment in a psychiatric clinic in Korea. METHODS: Fifty-seven patients with depression aged 60?years or over participated in the study. They were all low-income patients screened in the community and treated in a psychiatric clinic. The study design was a double-blind randomized controlled trial. The patients were randomly assigned to intervention (n?=?29) or usual care (n?=?28) groups. Intervention patients received depression care management for 6?months. Primary endpoint was an increase in remission rate as assessed using the 17-item Hamilton Depression Rating Scale score at 6?months. Secondary endpoints included improvement in treatment adherence, improvement in health-related quality of life, and a reduction in feelings of hopelessness. RESULTS: Patients in the care management intervention group showed a higher remission rate than those in the usual care group (55% vs. 29%, p?=?0.0421). Intervention patients were significantly more likely to adhere to the treatment (59% vs. 18%, p?=?0.0016). The hopelessness score at the 6-month assessment was significantly lower in the intervention group than the usual care group (23.5 vs. 25.7, p?=?0.0443). However, there was not a significant group difference in the quality of life. CONCLUSIONS: We found that care management not only contributed to reducing depressive symptoms in geriatric patients suffering from depression but also increased the treatment adherence rate, which in turn increased the remission rate. Care management intervention is both feasible and effective in psychiatric clinics in Korea. Copyright © 2012 John Wiley & Sons, Ltd.
HubMed – depression

 

Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases.

Filed under: Depression Treatment

J Gastroenterol. 2012 Dec 20;
Grover M, Camilleri M

The effects of antidepressants on the gastrointestinal tract may contribute to their potential efficacy in functional dyspepsia and irritable bowel syndrome; buspirone, a prototype 5-HT1A agonist, enhances gastric accommodation and reduces postprandial symptoms in response to a challenge meal. Paroxetine, a selective serotonin reuptake inhibitor, accelerates small bowel but not colonic transit, and this property may not be relevant to improve gut function in functional gastrointestinal disorders. Venlafaxine, a prototype serotonin norepinephrine reuptake inhibitor, enhances gastric accommodation, increases colonic compliance and reduces sensations to distension; however, it is associated with adverse effects that reduce its applicability in treatment of functional gastrointestinal disorders. Tricyclic antidepressants reduce sensations in response to food, including nausea, and delay gastric emptying, especially in females. Buspirone appears efficacious in functional dyspepsia; amitriptyline was not efficacious in a large trial of children with functional gastrointestinal disorders. Clinical trials of antidepressants for treatment of irritable bowel syndrome are generally small. The recommendations of efficacy and number needed to treat from meta-analyses are suspect, and more prospective trials are needed in patients without diagnosed psychiatric diseases. Antidepressants appear to be more effective in the treatment of patients with anxiety or depression, but larger prospective trials assessing both clinical and pharmacodynamic effects on gut sensorimotor function are needed.
HubMed – depression

 

“Human immunodeficiency virus serostatus disclosure-Rate, reactions, and discrimination”: A cross-sectional study at a rural tertiary care hospital.

Filed under: Depression Treatment

Indian J Dermatol Venereol Leprol. 2013 Jan; 79(1): 135
Joge US, Deo DS, Choudhari SG, Malkar VR, Ughade HM

Background: From the moment scientists identified Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), social responses of fear, denial, stigma, and discrimination have accompanied the epidemic. Aims: To assess the rate of disclosure of HIV serostatus, reactions by the HIV/AIDS patients and their spouse, and discrimination faced by the patients. Methods: The present cross-sectional study was conducted at Antiretroviral Therapy (ART) center of a rural tertiary care hospital, situated in Marathawada region of Maharashtra state from November 2008 to October 2010. Totally, 801 HIV-positive patients coming to ART center for treatment were included after ensuring confidentiality and taking informed consent. A preformed questionnaire was used to enquire about reaction after diagnosis, disclosure, and discrimination faced by the patients. The data analyzed using descriptive statistics and Chi-square test. Results: The most common immediate reaction by the HIV patients after getting diagnosed as seropositive was fear (593, 74.03%) followed by depression (385, 48.06%) and suicidal thoughts (98, 12.25%). Out of 801 patients, 769 (96%) had spouse and of these maximum number of patients (653, 84.92%) had disclosed HIV status to their spouses. Most common immediate reaction by spouse after disclosure was crime (324, 42.13%) followed by horror (294, 38.23%) and anger (237, 36.29%). Maximum number of patients were discriminated by friends (120, 71.01%) followed by discrimination at workplace (49, 67.12%), by neighbors (32, 56.14%), and by relatives (53, 43.80%). Conclusion: Male positives were granted greater acceptance, care, and support by their spouses. More percentage of females discriminated by neighbors, relatives, and friends and at workplace which might be due to factors like customs, morals, and taboos.
HubMed – depression

 

Treatment Plans and Interventions for Depression and Anxiety Disorders

$8.60
End Date: Monday Nov-4-2019 18:48:22 PST
Buy It Now for only: $8.60
Buy It Now | Add to watch list

 

Treatment for Chronic Depression : Cognitive Behavioral Analysis... (NoDust)
$7.13
End Date: Tuesday Nov-12-2019 13:18:09 PST
Buy It Now for only: $7.13
Buy It Now | Add to watch list

 

Stop Being Depressed, End Depression Treatment, Cure w/ Subliminal Hypnosis CD
$19.99
End Date: Saturday Nov-2-2019 19:38:23 PDT
Buy It Now for only: $19.99
Buy It Now | Add to watch list

 

Find More Depression Treatment Information…